Dr. Eastham describes updates to AUA guideline for clinically localized prostate cancer
The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.
The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.
Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.
“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
“And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management,”…
The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug,…
Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.
“Within this paper, we discussed the importance of conservative management and lifestyle modifications as initial steps in managing BPH,” says Eiftu S. Haile, MD.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with…
Both the SOLAR-STAGE and SOLAR-RECUR trials are currently enrolling patients with prostate cancer in the US, with additional sites expected to open in Europe later…